免疫治疗相关的疗效评价术语 - qitaijk.cn
持续临床获益（durable clinical benefit，DCB）：包括CR，PR和SD>6个月的患者. 无持续获益（non-durable clinical benefit，NDB)：包括SD⩽6个月和PD的患者. 【参考文献】 Molecular …
OS、DFS、PFS、CR、PR、SD、PD，ORR，DCR都是啥？一文汇 …
疾病控制率指按照公认的缓解评价标准（如实体瘤 RECIST 1.1 版），肿瘤经治疗后获得缓解（PR+CR）和病变稳定（SD）并能维持最低时限要求的患者比例。 病变进展指肿瘤靶病灶最 …
6+思路带你了解基因突变标志物和免疫检查点抑制剂治疗效果的关 …
DCB定义为完全缓解 (CR)、部分缓解 (PR)或持续6个月以上的稳定疾病 (SD); 疾病进展 (PD)或稳定疾病 (SD)持续少于6个月视为无持久获益 (NDB)。 最终一共有来自五种癌症类型的386名接 …
Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting …
2022年1月10日 · Drug-coated balloons (DCBs) are an established treatment strategy for coronary artery disease. Randomized data on the application of DCBs in patients with an acute …
抗肿瘤治疗疗效评价术语 - qitaijk.cn
2019年7月25日 · 持续临床获益（durable clinical benefit，DCB）：包括CR，PR和SD>6个月的患者。 无持续获益（NDB）：包括SD⩽6个月和PD的患者。 作者：LAMP. 校对：小全 2019-07-25
Comparative stabilization mechanism of self-assembling fattigated ...
The in vitro release of GOC SDs was maintained at pH 1.2 and pH 6.8, while DCB alone was rapidly released and then degraded. The more GOC used, the more DCB release delayed. …
A comparison of three kinds of balloon dilatations for patients …
2025年3月29日 · The use of DCB seems least preferable, as they are associated with more hospitalization cost and few cases of clinical improvement. ... (IQR) or means ± standard …
Drug-Coated Balloon Angioplasty of the Side Branch
2025年1月14日 · DCB-BIF is the first powered, large, randomized controlled trial to compare the outcomes of a DCB vs NCB intervention for the SB in a large population with true coronary …
Comparative stabilization mechanism of self-assembling fattigated ...
4 天之前 · Brij® 58 SD (DCB: Brij® 58 = 1:10) slightly increased the DCB stability via micellization above CMC for a short period of time as compared to the DCB control. In contrast, XA had …
<br>外周动脉疾病干预：药物涂层球囊与药物 ... - X-MOL
2022年8月27日 · 该研究的目的是评估药物洗脱支架（des）和药物涂层球囊（dcb）治疗外周动脉疾病（pad）的当前趋势和长期耐久性。 背景。 PAD 影响着全球超过 2 亿人。